NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

This research protocol tests a new technique and devices that we have developed to treat functional mitral valve regurgitation, called transcatheter mitral valve cerclage annuloplasty, otherwise known as "cerclage". Functional mitral valve regurgitation is a condition caused by damaged heart muscle involving the left ventricle which results in mitral valve leakage. This leakage causes heart failure (breathlessness and lack of energy especially when walking or exercising, and hospital admissions for fluid buildup).

This is an early feasibility study (EFS) evaluation of special devices, permanently implanted in the heart, to perform mitral cerclage annuloplasty. Mitral cerclage annuloplasty is a catheter procedure performed under X-ray and ultrasound guidance without surgery. The cerclage devices compress the mitral valve like a purse-string. The cerclage device has a special feature that prevents a coronary artery from getting squeezed as part of this purse-string.

The protocol has been changed to allow patients who have mitral valve regurgitation despite prior Mitra-Clip treatment, and to allow patients who have symptomatic heart failure with mild mitral regurgitation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Functional Mitral Regurgitation Cardiovascular Diseases Heart Diseases Heart Failure Ventricular Dysfunction

Age range

21 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States

About this study

Functional mitral regurgitation (also known as secondary mitral regurgitation) is a common complication of left ventricular dysfunction. Ventricular dysfunction leads to dilation, which in turn leads to mitral annular dilation and leaflet traction. This causes a failure of coaptation of the otherwise intact leaflets of the mitral valve, leading to regurgitation through a central orifice between the mal-coapting leaflet tips. Functional mitral regurgitation contributes to heart failure symptoms. Transcatheter Mitral Cerclage Annuloplasty (TMCA) is a new catheter technique that reduces the septal-lateral dimension of the dilated annulus through circumferential compression, prevents extrinsic compression and entrapment of coronary arteries by incorporating a protection element, and exhibits planar discordance that achieves annular reduction even when the coronary sinus is anatomically located along the posterior left atrial wall. This is an entirely right-sided procedure and device.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

INCLUSION CRITERIA:

Adults age >=21 years
Symptomatic functional mitral valve regurgitation

Mild or greater mitral valve regurgitation, LVEF <= 0.50, and NYHA class III - IV heart failure
Moderate or greater mitral valve regurgitation and NYHA II - IV heart failure, irrespective of LV systolic function
On optimal medical therapy for at least one month
Left ventricular ejection fraction >=0.20 assessed by echocardiography, CT, or CMR
Suitable coronary venous anatomy for Transcatheter Mitral Cerclage Annuloplasty based on pre-procedural cardiac CT or coronary venogram
Concordance of the Study Eligibility Committee
If present, a MitraClip was implanted at least 30 days previously

Exclusion criteria

Subjects unable to consent to participate
Subjects unwilling to participate or unwilling to return for study follow-up activities.
Prior cardiac implanted electronic devices (CIED) likely to be entrapped by cerclage.

-- Candidates with coronary sinus or left ventricular pacing or defibrillation leads that are not likely to be entrapped by cerclage, evident on baseline CT or angiogram, are eligible to participate.

TAVR within 6 weeks
Intended concurrent structural heart procedure, such as aortic or tricuspid valve intervention
Aortic stenosis more than mild in severity
Single-leaflet MitraClip detachment, if present
Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures

Treatment and study plan

Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)

Device

The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.

Primary outcomes

The Primary Endpoint is Technical Success

Time frame: 1 minute following procedure discharge (Exit from the catheterization laboratory)
The primary endpoint is Technical success. This endpoint is measured at exit from the catheterization laboratory. All of the following must be present:
- Alive
- Successful deployment and correct positioning of a single intended Transcatheter Mitral Cerclage Annuloplasty (TMCA). Repositioning and recapture of the device, if needed, is not classified as failure.
- Retrieval of the TMCA delivery system
- Absence of TMCA-related coronary artery compression and absence of additional procedure such as percutaneous coronary intervention (PCI) to relieve coronary artery compression.
- No additional unplanned or emergency surgery or re-intervention related to the TMCA or delivery system.

Secondary outcomes

The Secondary Endpoint is Procedural Success

Time frame: Day 30 post procedure
The secondary endpoint is Procedural success This endpoint is measured at 30 days. All of the following must be present:
- Technical success
- No Transcatheter Mitral Cerclage Annuloplasty (TMCA) device-related Serious Adverse Events, defined as VARC-2 life-threatening bleeding, major vascular or cardiac complications related to the TMCA requiring unplanned reintervention or surgery.

Sponsors and collaborators

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Nih

Registry information

Important dates

Study start: 2019
Primary completion: 2021
Study completion: 2026
First posted: Apr 29, 2019
Registry last updated: Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed